ALLISON FELSHAW: Open Payments
NPI 1821398371 · OREM, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,821 in 95 payments from 29 companies in 2025. Trend: 2023 $1,934 · 2024 $1,833 · 2025 $1,821
Food & beverage: $1,821
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $352 |
| Astellas Pharma US Inc | 6 | $129 |
| Amgen Inc. | 7 | $118 |
| Otsuka America Pharmaceutical, Inc. | 6 | $114 |
| PFIZER INC. | 6 | $99 |
| Novo Nordisk Inc | 5 | $93 |
| Viatris Specialty LLC | 3 | $81 |
| GlaxoSmithKline, LLC. | 5 | $80 |
| Boston Scientific Corporation | 3 | $74 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $72 |
Products named: VRAYLAR, REXULTI, Veozah, QULIPTA, JARDIANCE, EVENITY, UBRELVY, YUPELRI.
Industry payments across UT — which companies pay providers there.
